597359 The disclosure relates to the use of active charcoal for the manufacture of a medicament for the treatment of an overdose of dabigatran etexilate (formula I). The medicament may be formulated for oral administration with 20 – 130 g of charcoal. The disclosure also relates to the use of charcoal for the manufacture of a medicament for absorbing dabigatran from blood plasma.